ZymoGenetics has received FDA approval to market rThrombin, a surgical blood clotting product. The drug is a recombinant form of human thrombin; previous treatments were derived from human or animal blood. ZymoGenetics says that production of the new drug doesn't depend on the availability of animal or human blood and can therefore be scaled-up to meet market demand.
The drug, to be sold under the name Recothrom, was acquired by Bayer last year in a $198 million deal [1]. The FDA approval triggers a $40 million milestone payment to ZymoGenetics.
- see this release [2] for more
ALSO: Check out the 17 new drugs that received FDA approval last year. List [3]
Related Articles:
ZymoGenetics deal for rThrombin hits a hurdle. Report [4]
ZymoGenetics inks $198M deal. Report [1]
Pivotal Thrombin trial a success for ZymoGenetics. Report [5]
ZymoGenetics builds cash reserves as it advances Thrombin. Report [6]
Links:
[1] http://www.fiercebiotech.com/story/spotlight-zymogenetics-inks-198m-deal/2007-06-19
[2] http://www.fiercebiotech.com/press-releases/us-fda-approves-recothrom
[3] http://www.fiercebiotech.com/special-reports/2007-fda-approvals
[4] http://www.fiercebiotech.com/story/zymogenetics-deal-rthrombin-hits-hurdle/2007-08-23
[5] http://www.fiercebiotech.com/story/pivotal-thrombin-trial-a-success-for-zymogenetics/2006-09-06?utm_medium=rss&utm_source=rss
[6] http://www.fiercebiotech.com/story/zymogenetics-builds-cash-reserves-as-it-advances-thrombin/2005-08-05